Bad Blood

The Financial Times & McKinsey Business Book of the Year

A New York Times Notable Book
A Washington Post Notable Book

One of the Best Books of the Year: NPR, San Francisco Chronicle, Time, Esquire, Fortune, Marie Claire, GQ, Mental Floss, Science Friday, Bloomberg, Popular Mechanics, BookRiot, The Seattle Times, The Oregonian, Publishers Weekly, Library Journal

In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.5 billion. There was just one problem: The technology didn't work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings-from journalists to their own employees.

Rigorously reported and fearlessly written, Bad Blood is a gripping story of the biggest corporate fraud since Enron-a tale of ambition and hubris set amid the bold promises of Silicon Valley.

John Carreyrou, a two-time Pulitzer Prize winner, was a reporter at The Wall Street Journal for twenty years. For his extensive coverage of Theranos, Carreyrou was awarded the George Polk Award for Financial Reporting, the Gerald Loeb Award for Distinguished Business and Financial Journalism in the category of beat reporting, and the Barlett & Steele Silver Award for Investigative Business Journalism. Bad Blood was named the Financial Times and McKinsey Business Book of the Year. Carreyrou lives in Brooklyn, New York, with his wife and three children.